Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$12.27 +1.6%	$9.48	$6.42 ▼ $12.53	$1.59B	1.23	2.80 million shs	2.02 million shs
CDTX Cidara Therapeutics	$66.37 -1.7%	$53.69	$10.14 ▼ $69.36	$1.71B	1.18	425,951 shs	558,355 shs
CMPS COMPASS Pathways	$4.61 +7.0%	$3.95	$2.25 ▼ $8.54	$413.51M	2.17	1.79 million shs	2.36 million shs
IMCR Immunocore	$32.93 +0.8%	$33.30	$23.15 ▼ $39.33	$1.66B	0.77	328,243 shs	289,496 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+1.57%	0.00%	+33.51%	+51.86%	+86.19%
CDTX Cidara Therapeutics	-1.66%	+1.78%	+2.34%	+173.35%	+410.54%
CMPS COMPASS Pathways	+6.96%	+6.71%	-0.22%	+5.73%	-34.52%
IMCR Immunocore	+0.80%	+0.15%	-8.65%	+5.68%	-9.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.6434 of 5 stars	1.5	3.0	0.0	3.4	2.5	2.5
CDTX Cidara Therapeutics	3.5877 of 5 stars	2.6	3.0	4.6	2.3	1.7	0.0
CMPS COMPASS Pathways	2.5555 of 5 stars	3.4	3.0	0.0	2.7	0.8	0.6
IMCR Immunocore	1.7879 of 5 stars	3.3	1.0	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	-2.20% Downside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-3.36% Downside
CMPS COMPASS Pathways	2.86	Moderate Buy	$16.29	253.27% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	76.13% Upside

Current Analyst Ratings Breakdown

Latest CMPS, IMCR, AUPH, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
8/1/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	6.87	$0.31 per share	39.17	$2.55 per share	4.81
CDTX Cidara Therapeutics	$1.27M	1,325.31	N/A	N/A	$19.76 per share	3.36
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$1.69 per share	N/A
IMCR Immunocore	$356.15M	4.66	N/A	N/A	$7.71 per share	4.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	28.54	21.91	N/A	23.31%	20.06%	13.81%	11/6/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.84	N/A	N/A	N/A	N/A	-87.89%	-57.77%	10/30/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)

Latest CMPS, IMCR, AUPH, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.37	-$0.38	-$0.01	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
CDTX Cidara Therapeutics	N/A	16.45	16.45
CMPS COMPASS Pathways	0.16	8.82	8.82
IMCR Immunocore	1.01	5.89	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CDTX Cidara Therapeutics	35.82%
CMPS COMPASS Pathways	46.19%
IMCR Immunocore	84.50%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
CDTX Cidara Therapeutics	3.89%
CMPS COMPASS Pathways	3.93%
IMCR Immunocore	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
CMPS COMPASS Pathways	120	95.94 million	92.17 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable

CMPS, IMCR, AUPH, and CDTX Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Buys 351,610 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

August 23 at 6:45 AM | marketbeat.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by Analysts

August 19, 2025 | marketbeat.com

Q3 Earnings Forecast for Immunocore Issued By HC Wainwright

August 16, 2025 | marketbeat.com

What is HC Wainwright's Estimate for Immunocore Q3 Earnings?

August 16, 2025 | americanbankingnews.com

Immunocore FY2027 EPS Forecast Increased by HC Wainwright

August 15, 2025 | marketbeat.com

FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright

August 14, 2025 | americanbankingnews.com

Persistent Asset Partners Ltd Purchases New Stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 13, 2025 | marketbeat.com

Immunocore’s Earnings Call Highlights Robust Growth and Strategic Expansion

August 13, 2025 | msn.com

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Immunocore (NASDAQ:IMCR) Cut to Hold at Wall Street Zen

August 10, 2025 | marketbeat.com

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Immunocore Holdings plc 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...

August 8, 2025 | finance.yahoo.com

Immunocore (IMCR) Q2 Revenue Jumps 30%

August 8, 2025 | aol.comA

Primecap Management Co. CA Increases Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 8, 2025 | marketbeat.com

Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

August 7, 2025 | zacks.com

Immunocore reports second quarter financial results and provides a business update

August 7, 2025 | globenewswire.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Shares Sold by BIT Capital GmbH

August 4, 2025 | marketbeat.com

TD Asset Management Inc Reduces Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 2, 2025 | marketbeat.com

Immunocore (IMCR) Expected to Announce Quarterly Earnings on Thursday

August 1, 2025 | marketbeat.com

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

July 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, IMCR, AUPH, and CDTX Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.27 +0.19 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.14 -0.13 (-1.06%)

As of 08/22/2025 07:47 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Cidara Therapeutics NASDAQ:CDTX

$66.37 -1.12 (-1.66%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$66.87 +0.50 (+0.75%)

As of 08/22/2025 06:08 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

COMPASS Pathways NASDAQ:CMPS

$4.61 +0.30 (+6.96%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.02 (-0.43%)

As of 08/22/2025 07:53 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Immunocore NASDAQ:IMCR

$32.93 +0.26 (+0.80%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$33.01 +0.08 (+0.23%)

As of 08/22/2025 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time